Summary
arGEN-X BV (arGEN-X) discovers and develops antibody drugs based on its proprietary antibody platforms. Its product pipeline includes ARGX-110, ARGX-111 and ARGX-115 for the treatment of various types of cancers such as T-cell lymphoma, nasopharyngeal cancer, chronic myelogenous leukemia, MET amplified cancer and others. ARGX-113 and ARGX-110 are for the treatment of autoimmune diseases. arGEN-X develops antibodies using its proprietary technology platforms such as NHance, SIMPLE antibody technology and others. The company’s products are used for the treatment of cancer and inflammatory and autoimmune diseases. It has operations in the Netherlands and Belgium. arGEN-X is headquartered in Breda, the Netherlands.
arGEN-X BV (ARGX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
arGEN-X BV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
arGEN-X BV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
arGEN-X BV, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
arGEN-X Raises US$6.7 Million In Extended Series B Financing 11
arGEN-X Secures US$37 Million In Series B Financing Round 12
Partnerships 14
Argen-X to Partner with AbbVie 14
Tetragenetics Enters into Agreement with arGEN-X, Crystal Biosciences and Sevion Therapeutics 15
arGEN-X Enters into Co-Development Agreement with Leo Pharma 16
arGEN-X Enters into Agreement with Bayer Pharma To Discover and Develop Therapeutic Antibody Candidates 17
Argen-X Expands Co-Development Agreement With Shire For Additional Therapeutic Antibody 18
arGEN-X Enters Into Co-Development Agreement With Shire For Therapeutic Antibody 19
Licensing Agreements 20
Staten Biotech Exercises Option for Licensing Agreement with Argen-X for ARGX-116 20
Shire Extends its Licensing Agreement with ArGEN-X 21
ArGEN-X Enters into Licensing Agreement with University of Bern 22
Lonza Enters into Licensing Agreement with arGEN-X 22
Biowa And Lonza Enter Into Licensing Agreement With arGEN-X For Potelligent CHOK1SV 23
arGEN-X Enters Into Licensing Agreement With de Duve Institute 24
ArGEN-X Enters Into Licensing Agreement For NHance Technology 25
RuiYi Enters Into Licensing Agreement With arGEN-X For ARGX-109 26
arGEN-X Enters Into Licensing Agreement With University of Texas Southwestern Medical Center For NHance Technology 27
arGEN-X Enters Into Licensing Agreement With Biowa 28
arGEN-X Enters Into Licensing Agreement With Eli Lilly 29
Equity Offering 30
Argenx Files Draft Registration Statement for Public Offering of Shares 30
Argenx Raises USD33.4 Million in Private Placement of Shares 30
arGEN-X Raises USD17.4 Million in Private Placement of Shares 32
arGEN-X Completes Exercise of Underwriter's Over Allotment Option for IPO for USD56.8 Million 33
arGEN-X BV - Key Competitors 36
Key Employees 37
Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39
List of Tables
arGEN-X BV, Pharmaceuticals & Healthcare, Key Facts, 2015 1
arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
arGEN-X BV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
arGEN-X BV, Deals By Therapy Area, 2011 to YTD 2017 8
arGEN-X BV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
arGEN-X Raises US$6.7 Million In Extended Series B Financing 11
arGEN-X Secures US$37 Million In Series B Financing Round 12
Argen-X to Partner with AbbVie 14
Tetragenetics Enters into Agreement with arGEN-X, Crystal Biosciences and Sevion Therapeutics 15
arGEN-X Enters into Co-Development Agreement with Leo Pharma 16
arGEN-X Enters into Agreement with Bayer Pharma To Discover and Develop Therapeutic Antibody Candidates 17
Argen-X Expands Co-Development Agreement With Shire For Additional Therapeutic Antibody 18
arGEN-X Enters Into Co-Development Agreement With Shire For Therapeutic Antibody 19
Staten Biotech Exercises Option for Licensing Agreement with Argen-X for ARGX-116 20
Shire Extends its Licensing Agreement with ArGEN-X 21
ArGEN-X Enters into Licensing Agreement with University of Bern 22
Lonza Enters into Licensing Agreement with arGEN-X 22
Biowa And Lonza Enter Into Licensing Agreement With arGEN-X For Potelligent CHOK1SV 23
arGEN-X Enters Into Licensing Agreement With de Duve Institute 24
ArGEN-X Enters Into Licensing Agreement For NHance Technology 25
RuiYi Enters Into Licensing Agreement With arGEN-X For ARGX-109 26
arGEN-X Enters Into Licensing Agreement With University of Texas Southwestern Medical Center For NHance Technology 27
arGEN-X Enters Into Licensing Agreement With Biowa 28
arGEN-X Enters Into Licensing Agreement With Eli Lilly 29
Argenx Files Draft Registration Statement for Public Offering of Shares 30
Argenx Raises USD33.4 Million in Private Placement of Shares 30
arGEN-X Raises USD17.4 Million in Private Placement of Shares 32
arGEN-X Completes Exercise of Underwriter's Over Allotment Option for IPO for USD56.8 Million 33
arGEN-X BV, Key Competitors 36
arGEN-X BV, Key Employees 37
arGEN-X BV, Subsidiaries 38
List of Figures
arGEN-X BV, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
arGEN-X BV, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
